| Revenue and Practice Management |
1 |
1 |
| Dermatomyositis |
0 |
0.99 |
| Intravenous |
0 |
0.13 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.98 |
| Muscle |
0 |
0.13 |
| Muscle Biopsy |
0 |
0.13 |
| Myositis |
0 |
0.13 |
| Thrombus |
0 |
0.1 |
| Blood |
0 |
0.09 |
| Glucocorticoid |
0 |
0.09 |
| Immunoglobulin A (IgA) |
0 |
0.09 |
| Weakness |
0 |
0.09 |
| Immunoglobulin G (IgG) |
0 |
0.08 |
| Headache |
0 |
0.05 |
| Thromboembolism |
0 |
0.05 |
| Biopsy |
0 |
0.04 |
| California |
0 |
0.04 |
| Clinical Guidelines |
0 |
0.04 |
| Europe |
0 |
0.04 |
| Fever |
0 |
0.04 |
| Financial Reimbursement |
0 |
0.04 |
| Hospital |
0 |
0.04 |
| Immunology |
0 |
0.04 |
| Immunosuppressive Therapy |
0 |
0.04 |
| Insurance |
0 |
0.04 |
| Nausea |
0 |
0.04 |
| Plasma |
0 |
0.04 |
| Residency |
0 |
0.04 |
| Rheumatic Disease |
0 |
0.04 |
| Severity Index |
0 |
0.04 |
| Texas |
0 |
0.04 |